Regeneron Pharmaceuticals Inc (REGN)

Cash ratio

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash and cash equivalents	US$ in thousands	2,488,200	2,730,000	3,105,900	2,885,600	2,193,700
Short-term investments	US$ in thousands	6,524,300	8,114,800	4,636,400	2,809,100	1,393,300
Total current liabilities	US$ in thousands	3,944,300	3,423,400	3,141,300	3,932,500	2,697,400
Cash ratio		2.28	3.17	2.46	1.45	1.33

December 31, 2024 calculation

Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($2,488,200K + $6,524,300K) ÷ $3,944,300K
= 2.28

The cash ratio of Regeneron Pharmaceuticals Inc has exhibited an upward trend over the past five years, increasing from 1.33 in December 2020 to 2.28 in December 2024. This indicates that the company's ability to cover its short-term liabilities with its cash and cash equivalents has improved steadily. A higher cash ratio suggests that Regeneron Pharmaceuticals Inc holds an increased level of liquid assets relative to its current liabilities, providing a strong financial position in terms of liquidity. The company's cash management and financial stability appear to be on a positive trajectory based on the consistent growth in the cash ratio.